ReviewJournal of neuro-oncology2022
Radiation myelopathy following stereotactic body radiation therapy for spine metastases.
Review in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Comparison of Titanium and Carbon Fiber-Reinforced Polyetheretherketone Spinal Implants in Postoperative Spine Stereotactic Body Radiation Therapy: A Comprehensive Review of Current Evidence and Future Perspectives.Advances in radiation oncology · 2026Review
- Spine surgery for metastatic spine cancer in the era of advanced radiation therapy.Asian spine journal · 2026Article
- Using Time-Staged Palliative Conventional Radiation Therapy Followed by Stereotactic Body Radiation Therapy in Malignant Epidural Extension for a Nonsurgical Candidate.Advances in radiation oncology · 2025Article
- Efficacy of Radiotherapy for Oligometastatic Lung Cancer and Irradiation Methods Based on Metastatic Site.Cancers · 2025Review
- Efficacy of a thermoplastic mask and pneumatic abdominal compression device for immobilization in stereotactic ablative radiotherapy of spine metastases.Journal of applied clinical medical physics · 2025Article
- Radiation Myelitis Risk After Hypofractionated Spine Stereotactic Body Radiation Therapy.JAMA oncology · 2025Article
- Image-guided treatment of mouse tumours with radioactive ion beams.Nature physics · 2025Article
- Compound 7 regulates microglia polarization and attenuates radiation-induced myelopathy via the Nrf2 signaling pathway in vivo and in vitro studies.Molecular medicine (Cambridge, Mass.) · 2024Article
- Stereotactic body radiotherapy for treatment of spinal metastasis: A systematic review of the literature.Neuro-oncology advances · 2024Review
- Optimal timing for local ablative treatment of bone oligometastases in non-small cell lung cancer.Journal of bone oncology · 2023Review
- Stereotactic Body Radiation Therapy for Spine Metastases-Findings from an Australian Population-Based Study.Current oncology (Toronto, Ont.) · 2023Article
- Progressive resolution optimizer (PRO) predominates over photon optimizer (PO) in sparing of spinal cord for spine SABR VMAT plans.BMC cancer · 2023Article
- Dosimetric and Radiobiological Impact of Patient Setup Errors in Intensity-modulated Radiotherapy for Esophageal Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStereotactic body radiation therapy (SBRT) is now considered a standard of care treatment option in the management of spine metastases. One of the most feared complications of spine SBRT is radiation myelopathy (RM).
methodsWe provided a narrative review of RM following spine SBRT based on review of the published literature, including data on spinal cord dose constraints associated with the risk of RM, strategies to mitigate the risk, and management options for RM.
resultsThere are limited published data of cases of RM following spine SBRT with detailed spinal cord dosimetry. The HyTEC report provided recommendations for the point maximal dose (Dmax) for the spinal cord that is associated with a < 5% risk of RM for 1-5 fractions spine SBRT. In the setting of spine SBRT reirradiation after previous conventional external beam radiation therapy (cEBRT), factors associated with RM are: SBRT spinal cord Dmax, cumulative spinal cord Dmax, and the time interval between previous RT and SBRT reirradiation. There are various strategies to mitigate the risk of RM, including accurate delineation of the spinal cord (or thecal sac), strict adherence to the recommended spinal cord dose constraints, and robust treatment immobilisation set-up and delivery. Limited effective treatment options are available for patients who develop RM, and these include corticosteroids, hyperbaric oxygen, and bevacizumab; however, none have been supported by high quality evidence.
conclusionRM is a rare but devastating complication following SBRT for spine metastases. There are strategies to minimise the risk of RM to ensure safe delivery of spine SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.